With longer terminal half-life time, MVT-602, a novel KISS1R agonist, has longer duration of kisspeptin targeted action of stimulating GnRH synthesis and sustaining peak GnRH levels, consequently promoting LH synthesis in women with PCOS. Here, GNRH1 is linked to polycystic ovary syndrome.